ADDED
The images found on pages 9, 10, 15, 21, 27 and 29 of this Annual Report were created with biorender.com.
Unless otherwise indicated, all information in this Annual Report on Form 10-K gives effect to the 1-for-30 reverse stock split of our common stock that became effective on June 5, 2025, and all references to shares of common stock outstanding and per share amounts give effect to the reverse stock split.
These cells serve as a functional bridge between innate and adaptive immunity, contributing to direct tumor-killing as well as immune cell recruitment and activation to drive deeper, more comprehensive immune responses.
Our platform employs allogeneic, autologous, induced pluripotent stem cell ("iPSC") and genetically modified cell therapy approaches, as well as TCEs that are designed to effectively identify and eradicate tumor or target cells.
We believe this lofty aspiration will one day be achievable and that it is our responsibility to directly contribute to global health efforts by pursuing scientific research that will advance the treatment of cancer and other diseases with unmet medical needs.
We currently have two novel programs in the clinic that have demonstrated durable complete remission in difficult to treat cancers.
To date, we have conducted two primary investigator-sponsored Phase 1 clinical trials evaluating our gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment.
INB-100 is assessing our DeltEx Allogeneic ( Allo ) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation ( HSCT ).
INB-200, evaluated our DeltEx Drug Resistant Immunotherapy ( DRI ) in patients with newly diagnosed glioblastoma ( GBM ).
Both trials have demonstrated encouraging clinical activity, including long-term durable remissions, with patients remaining alive and in remission or progression-free for more than four years.
REMOVED
The images found on pages 7, 9, 13, 19, 24, 26 and 27 of this Annual Report were created with biorender.com.
These cells serve as a functional bridge between innate and adaptive immunity to contribute to direct tumor-killing, as well as immune cell recruitment and activation to drive deeper and more comprehensive immune responses.
Our platform employs allogeneic, autologous, induced pluripotent stem cell ("iPSC"), genetically modified cell therapy approaches, and TCEs that are designed to effectively identify and eradicate tumor and targeted cells.
We believe this lofty aspiration will one day be achievable, and that it is our responsibility to directly contribute to related global health efforts by pursuing scientific research that will advance the treatment of cancer and other diseases with unmet needs Our DeltEx platform is designed to overcome many of the challenges associated with the expansion, genetic engineering, and scalable manufacturing of gamma-delta T cells.
We currently have two novel programs in the clinic that have demonstrated durable complete tumor remissions.
To date, we have conducted two main investigator-sponsored Phase 1 clinical trials to test our gamma-delta T cell technologies in cancer patients.
INB-100 tests our DeltEx Allogeneic ( Allo ) gamma-delta T cells in older patients with high-risk leukemias undergoing haploidentical stem cell transplantation ( HSCT ) and INB-200 tested our DeltEx Drug Resistant Immunotherapy ( DRI ) in newly diagnosed glioblastoma ( GBM ) patients.
Both trials have demonstrated long-term durable remissions with patients remaining alive and remission for greater than three years.
Furthermore, these AML patients demonstrated one-year progression-free survival ( PFS ) and overall survival ( OS ) rates, exceeding real-world control groups obtained from both the Center for International Blood and Marrow Transplant Research ( CIBMTR ) and historical patient outcomes data from the Kansas University Cancer Center ( KUCC ) where the study is currently being conducted.
To further de-risk this registrational pathway, we are currently enrolling in an expansion cohort, with a target of up to 25 patients, to confirm the improvements in relapse free and OS observed to date.